Disc Medicine Inc
IRON60.790USD
-1.840-2.94%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
2.11BValor de mercado
PerdaP/L TTM
Mais detalhes de Disc Medicine Inc Empresa
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Informações da empresa
Código da empresaIRON
Nome da EmpresaDisc Medicine Inc
Data de listagemAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Número de funcionários84
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 12
Endereço321 Arsenal Street, Suite 101
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Telefone16176749274
Sitehttps://www.discmedicine.com/
Código da empresaIRON
Data de listagemAug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
Outro
65.03%
Investidores
Investidores
Proporção
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
Outro
65.03%
Tipos de investidores
Investidores
Proporção
Investment Advisor
37.71%
Investment Advisor/Hedge Fund
18.24%
Hedge Fund
17.94%
Venture Capital
12.84%
Corporation
10.24%
Private Equity
9.90%
Research Firm
1.45%
Sovereign Wealth Fund
0.83%
Individual Investor
0.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
2023Q1
169
18.38M
96.84%
-1.35M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Access Industries, Inc.
3.56M
10.27%
--
--
Feb 27, 2025
Fidelity Management & Research Company LLC
3.05M
8.81%
+1.32M
+76.31%
Mar 31, 2025
Atlas Venture
2.38M
6.88%
-125.00K
-4.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.75M
5.06%
+219.74K
+14.35%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.75M
5.07%
--
--
Mar 31, 2025
RA Capital Management, LP
1.58M
4.55%
+1.58M
--
Mar 31, 2025
Janus Henderson Investors
1.42M
4.11%
+205.44K
+16.87%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.34M
3.87%
-36.42K
-2.65%
Mar 31, 2025
Wellington Management Company, LLP
2.34M
6.77%
+948.09K
+67.94%
Mar 31, 2025
OrbiMed Advisors, LLC
1.42M
4.09%
-370.55K
-20.75%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Proshares Ultra Russell 2000
0.06%
Global X Russell 2000 ETF
0.06%
ProShares UltraPro Russell2000
0.06%
First Trust US Equity Opportunities ETF
0.06%
iShares Morningstar Small-Cap Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Fidelity MSCI Health Care Index ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.09%
Proshares Ultra Russell 2000
Proporção0.06%
Global X Russell 2000 ETF
Proporção0.06%
ProShares UltraPro Russell2000
Proporção0.06%
First Trust US Equity Opportunities ETF
Proporção0.06%
iShares Morningstar Small-Cap Value ETF
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
Fidelity MSCI Health Care Index ETF
Proporção0.02%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Data
Tipo
Proporção
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
